Boothbay Fund Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Boothbay Fund Management’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,942	Closed	-$45.3K	–	2019
2023 Q4	$45.3K	Hold	12,942	–	–	﹤0.01%	1535
2023 Q3	$46.1K	Hold	12,942	–	–	﹤0.01%	1634
2023 Q2	$75.3K	Hold	12,942	–	–	﹤0.01%	1644
2023 Q1	$489K	Hold	12,942	–	–	0.01%	1262
2022 Q4	$386K	Hold	12,942	–	–	0.01%	1277
2022 Q3	$432K	Sell	12,942 -473	-4%	-$18.1K	0.01%	1306
2022 Q2	$537K	Hold	13,415	–	–	0.01%	1140
2022 Q1	$706K	Hold	13,415	–	–	0.02%	1112
2021 Q4	$743K	Hold	13,415	–	–	0.02%	871
2021 Q3	$1.04M	Sell	13,415 -1,287	-9%	-$109K	0.03%	740
2021 Q2	$1.91M	Hold	14,702	–	–	0.06%	399
2021 Q1	$2.42M	Hold	14,702	–	–	0.09%	260
2020 Q4	$3.44M	Buy	14,702 +2,887	+24%	+$402K	0.13%	148
2020 Q3	$1.22M	Buy	+11,815	New	+$633K	0.07%	372

Other funds holding TCON

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Boothbay Fund Management's TCON Position: Q1 2024 in Review

Boothbay Fund Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2024, closing a stake of 12,942 shares — an estimated $45.3K sold.

Boothbay Fund Management first reported a position in TCON in Q3 2020 and held it in 14 quarters. The position peaked at $3.44M in Q4 2020. 29 funds tracked by Wall St. Rank hold TCON as of Q1 2024.

Boothbay Fund Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Boothbay Fund Management sold 12,942 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $45.3K.
Boothbay Fund Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 14 quarters.
Boothbay Fund Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $3.44M in Q4 2020.
29 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.